Customer Login|Create an Account

Clinical Pipeline

ExeGi is focused on research and development of microbiome science and expanding the use of Visbiome in a variety of therapeutic areas.

Human Studies

Disease State

Primary Endpoint

Sponsor / Collaborator

Trial Design

Estimated Enrollment

Multiple Sclerosis

Pripheral Blood Mononuclear Cells (pBMCs), Serum Neurofilament Light Concentration

Newly Diagnose Type 1 Diabetes

Controlled vs prebiotic

20

Newly Diagnose Type 1 Diabetes

Effect of Multistrain Probiotic on Imnune System Inflammation as measured by plasma transcription analysis

Medical College of Wisconsin

Single Blind Placebo Controlled

60

HIV

Blood immune activation -Percent change in blood immune activation (co-expression of CD38 and HLA-DR) on CD8 T cells at week 48

Canadian HIV Trials Network

Double Blind Placebo Controlled

40

Autism Spectrum Disorder

Changes in severity level of ASD symptomatology, Delta of scores at Autism Diagnostic Observation Schedule-2

IRCCS Stella Maris Foundation, Ministry of Health Italy,

CNR Institute of Clinical Physiology

Double Blind Placebo Controlled**

100

Autism Spectrum Disorder

Change in Autism Treatment Evaluation Checklist (ATEC) -- 12 weeks of treatment

University College, London

Double Blind Placebo Controlled

110

Cirrhosis plus Spontaneous Bacterial Peritonitis

Changes in bacterial translocation.

Changes in systemic inflammatory response and systemic oxidative damage. 

Changes in cognitive function.

Foundation Research Institute of the Hospital de Sant Pau, Barcelona Spain

Double Blind Placebo Controlled**

30

Pre-Diabetic Adolescents

Change in microbiota composition

Change in microbiota composition (Secondary)

University of Seattle

Double Blind Placebo Controlled

16

Eradication of Extended Spectrum BetaLactam (ESBL) colonization in adults

Rate of participants that have changed from ESBL-negative to ESBL-negative.

Lund University

Double Blind Placebo Controlled

80

Portal Hypertension

Nocturnal systolic blood pressure -- 8 weeks

Charite University, Berlin, Germany

Double Blind Placebo Controlled

110

Severe Depression

Hamilton Depression Score

University Psychiatric Clinics, Basel, Switzerland

Double Blind Placebo Controlled

60

 

Veterinary Studies

Disease State

Primary Endpoint

Sponsor / Collaborator

Trial Design

Estimated Enrollment

Canine Inflammatory Bowel Disease

Dogs with IBD were randomized to receive either probiotic or combination drug therapy (Metronidazole/prednisone)

 

Evaluation with histology, CIBDAI, CD3+ cells, FoxP3+ cells, plasma, citrulline, microbiota analysis.

Texas A&M University, Iowa State University, University of Camerino (Italy)

Double Blind Randomized-Controlled

34 Dogs

Acute Hemorrhagic Diarrhea Syndrome (canine)

To evaluate the efficacy of probiotics in the treatment of acute hemorrhagic diarrheal syndrome in dogs and to characterize the changes in bacterial microbiota during the course of disease.

University of Munich

Controlled

60 Dogs

Please Note

You are now leaving Visbiome.com (USA) for Visbiome Canada.

Proceed to Visbiome Canada Stay on the US site